Maze Therapeutics Inc
MAZE
Company Profile
Business description
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Contact
171 Oyster Point boulevard
Suite 300, South San Francisco
San FranciscoCA94080
USAT: +1 650 850-5070
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Unconventional wisdom: A controversial income pick
Rigid definitions of income and growth shares may be holding investors back.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
Why ASX miners will handily beat banks in the long-term
After a stellar run for banks, investors are wondering whether they can continue their outperformance or if a rotation into miners is imminent. There’s a good case that a switch is coming, and it may last decades, not just years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,780.30 | 4.80 | -0.05% |
| CAC 40 | 7,973.03 | 34.59 | -0.43% |
| DAX 40 | 21,787.00 | 115.42 | -0.53% |
| Dow JONES (US) | 44,303.40 | 444.23 | -0.99% |
| FTSE 100 | 8,700.53 | 26.75 | -0.31% |
| HKSE | 21,133.54 | 241.92 | 1.16% |
| NASDAQ | 19,523.40 | 268.59 | -1.36% |
| Nikkei 225 | 38,787.02 | 279.51 | -0.72% |
| NZX 50 Index | 12,902.19 | 57.60 | 0.45% |
| S&P 500 | 6,025.99 | 57.58 | -0.95% |
| S&P/ASX 200 | 8,511.40 | 9.30 | -0.11% |
| SSE Composite Index | 3,303.67 | 33.01 | 1.01% |